• LAST PRICE
    1.8000
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (1.6949%)
  • Bid / Lots
    1.7800/ 2
  • Ask / Lots
    1.8000/ 23
  • Open / Previous Close
    1.7500 / 1.7700
  • Day Range
    Low 1.7500
    High 1.8000
  • 52 Week Range
    Low 1.6000
    High 6.0948
  • Volume
    8,367
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.77
TimeVolumeNHWK
09:32 ET49601.7559
09:36 ET4001.79
09:39 ET10001.8
09:43 ET2401.8
09:45 ET1001.8
09:48 ET1001.8
09:50 ET3531.8
09:52 ET5571.8
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNHWK
NightHawk Biosciences Inc
44.4M
-1.2x
---
United StatesNOVN
Novan Inc
36.4M
-0.9x
---
United StatesALID
Allied Corp
55.2M
-2.0x
---
United StatesHYEX
Healthy Extracts Inc
21.6M
-21.1x
---
United StatesCOCP
Cocrystal Pharma Inc
26.3M
-0.7x
---
United StatesSISI
Shineco Inc
13.3M
-0.2x
---
As of 2022-10-04

Company Information

NightHawk Biosciences, Inc., formerly Heat Biologics, Inc., is a fully integrated biopharmaceutical company. The Company specializes in the end-to-end development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. It focuses on drug development through its integrated ecosystem of subsidiary companies, which includes Skunkworx Bio (Skunkworx), Heat Biologics (Heat), Pelican Therapeutics (Pelican), Scorpion Biological Services (Scorpion) and Elusys Therapeutics (Elusys). It offers three technology platform, namely gp96, which leverages the immune stimulatory properties of the heat shock protein gp96 to induce the immune system’s own response against cancer and infectious disease; TNFRSF25, which targets the T cell co-stimulator TNFRSF25 to regulate inflammation and immunosuppression, and RapidVax designed to induce immunological memory against emerging biological threats and accelerate timeline to the clinic.

Contact Information

Headquarters
627 DAVIS DRIVE, SUITE 400MORRISVILLE, NC, United States 27560
Phone
919-240-7133
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Jeffrey Wolf
Chief Financial Officer, Controller, Secretary
William Ostrander
Lead Independent Director
John Prendergast
Independent Director
John Monahan
Independent Director
Edward Smith

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$44.4M
Revenue (TTM)
$1.4M
Shares Outstanding
25.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.37
EPS
$-1.55
Book Value
$4.41
P/E Ratio
-1.2x
Price/Sales (TTM)
32.2
Price/Cash Flow (TTM)
---
Operating Margin
-2,775.79%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.